Durect Corporation (DRRX)

Name: Durect Corporation (DRRX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Durect Corporation (DRRX)

Stock Card

$1.91

$0.00 (0.00%)

As on 11-Sep-2025 09:30EDT

Market cap

$59 Mln

Revenue (TTM)

$3 Mln

P/E Ratio

P/B Ratio

Div. Yield

0 %

Durect Corporation (DRRX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 1.91 High: 1.91

52 Week Range

Low: 0.48 High: 2.64

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-3.1 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-2.5
Debt to Equity

0
Book Value

$--
EPS

$-0.1
Face value

--
Shares outstanding

31,054,200

10 Years Aggregate

CFO

$-208.76 Mln

EBITDA

$-231.59 Mln

Net Profit

$-234.94 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Durect Corporation (DRRX)	154.7	2.1	232.2	27.3	-33.5	-34.7	-21.9
BSE Sensex^*	-9.1	-1.2	2.9	-3.6	5.7	6.2	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 11-Sep-2025 | *As on 31-Aug-2026 | #As on 26-Oct-2023

Company	2024	2023	2022	2021	2020	2019	2018
Durect Corporation (DRRX)	26.9	-82.9	-65.1	-52.2	-45.5	686.6	-47.4
S&P Small-Cap 600	7.0	13.9	-17.4	25.3	9.6	20.9	-9.7
BSE Sensex	8.1	18.7	4.4	22.0	15.8	14.4	5.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Durect Corporation (DRRX)

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in... lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment of patients with metabolic dysfunction-associated steatohepatitis. The company also offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; PERSERIS, an injectable suspension for the treatment of schizophrenia in adults; and Methydur to treat attention deficit hyperactivity disorder. It has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. As of September 11, 2025, DURECT Corporation operates as a subsidiary of Bausch Health Americas, Inc. Read more

Co-Founder, CEO, President & Director

Dr. James E. Brown D.V.M.
Co-Founder, CEO, President & Director

Dr. James E. Brown D.V.M.
Headquarters

Cupertino, CA
Website

https://www.durect.com

FAQs for Durect Corporation (DRRX)

What is the current share price of Durect Corporation (DRRX) Today?

The share price of Durect Corporation (DRRX) is $1.91 (NASDAQ) as of 11-Sep-2025 09:30 EDT. Durect Corporation (DRRX) has given a return of -33.47% in the last 3 years.

What is the current PB & PE ratio of Durect Corporation (DRRX)?

Since, TTM earnings of Durect Corporation (DRRX) is negative, P/E ratio is not available.
The P/B ratio of Durect Corporation (DRRX) is 17.03 times as on 11-Sep-2025, a 229 premium to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2024	-2.83	2.58
2023	-0.64	1.20
2022	-2.23	3.16
2021	-0.62	0.39
2020	-3.26	1.09

What is the 52 Week High and Low of Durect Corporation (DRRX)?

The 52-week high and low of Durect Corporation (DRRX) are Rs 2.64 and Rs 0.48 as of 31-Aug-2026.

What is the market cap of Durect Corporation (DRRX)?

Durect Corporation (DRRX) has a market capitalisation of $ 59 Mln as on 11-Sep-2025. As per SEBI classification, it is a Small Cap company.

Should I invest in Durect Corporation (DRRX)?

Before investing in Durect Corporation (DRRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.